Table 2 Characteristics for all participants.
Characteristic | cART-naïve (n = 20) | cART-treated inadequate responders (n = 20) | cART-treated responders (n = 20) | Noninfected controls (n = 20) | P valuea |
|---|---|---|---|---|---|
Age, years (IQRb) Sex | 40.5 (34.3–52.8) | 52.0 (43.0–64.5) | 46.5 (43.0–51.0) | 47.5 (35.0–55.0) | 0.08 |
Male, no. | 17 | 14 | 12 | 16 | — |
Female, no. | 3 | 6 | 8 | 4 | — |
CD4+ cell count inclusion date, median cells/µL (IQR) | 555 (385–743) | 320 (280–378) | 790 (640–1000) | — | <0.0001 |
Nadir CD4+ cell count, median cells/µL (IQR) | 480 (385–613) | 63 (20–39) | 197 (119–340) | — | <0.0001 |
HIV RNA level, median log(copies/mL) (IQR) | 4.2 (3.6–5.0) | — | — | — | — |
Duration of cART, median years (IQR) | — | 5.6 (4.4–7.2) | 10.1 (7.7–14.5) | — | 0.0005 |
Previremic index, median log(copies/mL) (IQR) | — | 4.9 (4.3–6.1) | 5.0 (4.7–5.8) | — | 0.96 |
Monocyte percentage, % (IQR) | 18.9 (12.2–25.6) | 22.4 (16.2–29.0) | 19.4 (15.4–22.9) | 20.2 (15.1–23.4) | 0.48 |